Factors influencing the production of recombinant SV40 vectors

被引:12
|
作者
Vera, M
Prieto, J
Strayer, DS
Fortes, P
机构
[1] Univ Navarra, Sch Med, Fdn Appl Med Res, Div Gene Therapy,Lab Vector Dev, Pamplona 31008, Spain
[2] Jefferson Med Coll, Dept Pathol & Cell Biol, Philadelphia, PA 19107 USA
关键词
SV40; recombinant SV40 vectors; gene therapy; production; titration; DI particles; wtSV40; revertants;
D O I
10.1016/j.ymthe.2004.06.1014
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Most gene therapy approaches employ viral vectors for gene delivery. Ideally, these vectors should be produced at high titer and purity with well-established protocols. Standardized methods to measure the quality of the vectors produced are imperative, as are techniques that allow reproducible quantitation of viral titer. We devised a series of protocols that achieve high-titer production and reproducible purification and provide for quality control and titering of recombinant simian virus 40 vectors (rSV40s). rSV40s are good candidate vehicles for gene transfer: they are easily modified to be nonreplicative and they are nonimmunogenic. Further, they infect a wide variety of cells and allow long-term transgene expression. We report here these protocols to produce rSV40 vectors in high yields, describe their purification, and characterize viral stocks using quality control techniques that monitor the presence of wild-type SV40 revertants and defective interfering particles. Several methods for reproducible titration of rSV40 viruses have been compared. We believe that these techniques can be widely applied to obtain high concentrations of high-quality rSV40 viruses reproducibly.
引用
收藏
页码:780 / 791
页数:12
相关论文
共 50 条
  • [31] SV40 AS A VECTOR
    SAMBROOK, J
    TOPP, W
    BOTCHAN, M
    JOURNAL OF SUPRAMOLECULAR STRUCTURE, 1977, : 49 - 49
  • [32] SV40 and mesothelioma
    Carbone, Michele
    Bertino, Pietro
    Qi, Fang
    Rivera, Zeyana
    Strianese, Oriana
    Zhang, Lei
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S72 - S72
  • [33] SV40 MORPHOGENESIS
    BINA, M
    BLASQUEZ, V
    NG, SC
    BEECHER, S
    COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, 1982, 47 : 565 - 569
  • [34] EFFECT OF INTERFERON ON SV40 T ANTIGEN PRODUCTION IN SV40-TRANSFORMED CELLS
    OXMAN, MN
    BARON, S
    BLACK, PH
    TAKEMOTO, KK
    HABEL, K
    ROWE, WP
    VIROLOGY, 1967, 32 (01) : 122 - &
  • [35] Using recombinant SV40 vectors to deliver antioxidant and Anti-CXCR4 transgenes to prevent neuronal apoptosis
    Strayer, DS
    Branco, F
    MOLECULAR THERAPY, 2003, 7 (05) : S92 - S92
  • [36] Comparative effectiveness of RNAi, ribozyme and single chain antibody delivered by recombinant SV40 vectors in silencing cellular proteins
    Cordelier, P
    Morse, B
    Rossi, J
    McKee, HM
    Strayer, DS
    MOLECULAR THERAPY, 2003, 7 (05) : S20 - S20
  • [37] SV40 vectors carrying minimal sequence of viral origin with exchangeable capsids
    Nakanishi, Akira
    Chapellier, Benoit
    Maekawa, Naoya
    Hiramoto, Masaki
    Kuge, Takeshi
    Takahashi, Ryo-u
    Handa, Hiroshi
    Imai, Takeshi
    VIROLOGY, 2008, 379 (01) : 110 - 117
  • [38] SV40 gene delivery vectors provide effective transgene expression in the eye
    Toscano, M. G.
    Diaz-Corrales, F. J.
    Rodriguez-Martinez, D.
    Camacho-Garcia, R. J.
    Bhatia, V.
    Herrera-Gomez, I.
    Valdez-Sanchez, L.
    van der Velden, J.
    van der Werf, S.
    Mancini, I.
    Gauthier, B.
    Pozo, D.
    Bhattacharya, S.
    de Haan, P.
    HUMAN GENE THERAPY, 2017, 28 (12) : A76 - A76
  • [39] FORMATION AND REPAIR OF ACETYLAMINOFLUORENE SV40 DNA, AND SV40 CHROMATIN ADDUCTS INVITRO
    VANLANCKER, JL
    TOMURA, T
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1980, 21 (MAR): : 111 - 111
  • [40] Highly purified, in vitro constructed SV40 vectors for in vivo gene delivery
    Mukherjee, S
    Bronstein, M
    Abd-El-Latif, M
    Ben-nun-Shau, O
    Oppenheim, A
    MOLECULAR THERAPY, 2004, 9 : S301 - S301